Orrick represented Kineta on the deal. Kineta, Inc., a clinical-stage biotechnology company focused on developing novel immunotherapies in oncology that address cancer immune resistance, has entered...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
